BB Biotech Q2 Net Loss Of CHF 87 Mln
July 26 (Reuters) -BB BIOTECH AG BION.S:
A NET LOSS OF CHF 87 MN WAS INCURRED IN Q2 COMPARED TO A NET LOSS OF CHF 13 MN IN PRIOR-YEAR PERIOD
A NET PROFIT OF CHF 173 MN WAS GENERATED DURING FIRST HALF OF 2024 COMPARED TO A NET LOSS OF CHF 267 MN IN SAME PERIOD OF 2023
BB BIOTECH'S SHARES CLOSED PERIOD 12.0% LOWER IN CHF AND 11.3% LOWER IN EUR
BOARD OF DIRECTORS HAS APPOINTED DR. CHRISTIAN KOCH, ONE OF TWO DEPUTY HEADS, AS NEW HEAD OF INVESTMENT MANAGEMENT TEAM EFFECTIVE JANUARY 1, 2025
DR. DANIEL KOLLER, WHO HAS SERVED AS HEAD OF BB BIOTECH'S INVESTMENT MANAGEMENT TEAM SINCE 2010, HAS INFORMED BOARD OF DIRECTORS OF HIS INTENTION TO RETIRE FROM HIS POSITION BY END OF 2024
TOTAL RETURN OF PORTFOLIO WAS -3.5% IN CHF, -2.6% IN EUR AND -3.3% IN USD
FOR FIRST SIX MONTHS OF 2024, TOTAL RETURN FOR BB BIOTECH'S SHARES WAS -2.0% IN CHF AND -4.6% IN EUR
PORTFOLIO PERFORMANCE WAS +7.3% IN CHF, +3.5% IN EUR, AND +0.4% IN USD
OUTLOOK: UPCOMING PRESIDENTIAL ELECTIONS IN USA COULD ALSO INFLUENCE SECTOR, PARTICULARLY THROUGH POSSIBLE CHANGES IN HEALTHCARE POLICY AND DRUG PRICES
OUTLOOK: INTEREST RATE DECISIONS REMAIN A PIVOTAL INFLUENCE ON BIOTECH INVESTMENTS
LEVEL OF INVESTMENT OF 113.5%
SHARE PRICE RETURN IN Q2 OF 2024 WAS -12.0% IN CHF AND -11.3% IN EUR
NET LOSS IN Q2 2024 AMOUNTED TO CHF 87 MN COMPARED TO A NET LOSS OF CHF 13 MN IN PRIOR-YEAR PERIOD
Source text for Eikon: ID:nEQ9RZ8mza
Further company coverage: BION.S
(Gdansk Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.